new deal, page-11

re: worth 2/3 whole company while I am a biota holder and think it's got very good prospects for the medium and long term, and RSV is a common and problematic childhood infection which i'd love to have something to offer patients for; one thing to bear in mind is that if an effective and cheap vaccine comes in then it's all over for BTA's treatment option. It then becomes worthless. I think the vaccine prospects for RSV are better than a pandemic flu vaccine, thus still putting Relenza as the backbone of this company at present. Which I still think makes it worth much more than the current share price, due to all the orders we will hear about eventually.